Switch theme
Sign up to access all valuation multiples
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
2010
113
LTM Revenue $1.8M
LTM EBITDA -$140M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CG Oncology has a last 12-month revenue (LTM) of $1.8M and a last 12-month EBITDA of -$140M.
In the most recent fiscal year, CG Oncology achieved revenue of $1.1M and an EBITDA of -$115M.
CG Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CG Oncology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.8M | XXX | $1.1M | XXX | XXX | XXX |
| Gross Profit | $1.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$140M | XXX | -$115M | XXX | XXX | XXX |
| EBITDA Margin | -7899% | XXX | -10064% | XXX | XXX | XXX |
| EBIT | -$139M | XXX | -$115M | XXX | XXX | XXX |
| EBIT Margin | -7796% | XXX | -10067% | XXX | XXX | XXX |
| Net Profit | -$112M | XXX | -$88.0M | XXX | XXX | XXX |
| Net Margin | -6290% | XXX | -7729% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, CG Oncology's stock price is $26.
CG Oncology has current market cap of $2.0B, and EV of $1.3B.
See CG Oncology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $2.0B | XXX | XXX | XXX | XXX | $-1.60 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, CG Oncology has market cap of $2.0B and EV of $1.3B.
CG Oncology's trades at 1111.7x EV/Revenue multiple, and -11.0x EV/EBITDA.
Equity research analysts estimate CG Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CG Oncology has a P/E ratio of -17.5x.
See valuation multiples for CG Oncology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.0B | XXX | $2.0B | XXX | XXX | XXX |
| EV (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 712.3x | XXX | 1111.7x | XXX | XXX | XXX |
| EV/EBITDA | -9.0x | XXX | -11.0x | XXX | XXX | XXX |
| EV/EBIT | -9.1x | XXX | -11.0x | XXX | XXX | XXX |
| EV/Gross Profit | 712.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -17.5x | XXX | -22.2x | XXX | XXX | XXX |
| EV/FCF | -11.4x | XXX | -16.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCG Oncology's last 12 month revenue growth is 2032%
CG Oncology's revenue per employee in the last FY averaged $10K, while opex per employee averaged $1.0M for the same period.
CG Oncology's rule of 40 is -25140% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CG Oncology's rule of X is -2818% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CG Oncology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2032% | XXX | 778% | XXX | XXX | XXX |
| EBITDA Margin | -7899% | XXX | -10064% | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -25140% | XXX | -8032% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -2818% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $10K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7208% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 10167% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CG Oncology acquired XXX companies to date.
Last acquisition by CG Oncology was XXXXXXXX, XXXXX XXXXX XXXXXX . CG Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was CG Oncology founded? | CG Oncology was founded in 2010. |
| Where is CG Oncology headquartered? | CG Oncology is headquartered in United States of America. |
| How many employees does CG Oncology have? | As of today, CG Oncology has 113 employees. |
| Who is the CEO of CG Oncology? | CG Oncology's CEO is Mr. Arthur Kuan. |
| Is CG Oncology publicy listed? | Yes, CG Oncology is a public company listed on NAS. |
| What is the stock symbol of CG Oncology? | CG Oncology trades under CGON ticker. |
| When did CG Oncology go public? | CG Oncology went public in 2024. |
| Who are competitors of CG Oncology? | Similar companies to CG Oncology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of CG Oncology? | CG Oncology's current market cap is $2.0B |
| What is the current revenue of CG Oncology? | CG Oncology's last 12 months revenue is $1.8M. |
| What is the current revenue growth of CG Oncology? | CG Oncology revenue growth (NTM/LTM) is 2032%. |
| What is the current EV/Revenue multiple of CG Oncology? | Current revenue multiple of CG Oncology is 712.3x. |
| Is CG Oncology profitable? | Yes, CG Oncology is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of CG Oncology? | CG Oncology's last 12 months EBITDA is -$140M. |
| What is CG Oncology's EBITDA margin? | CG Oncology's last 12 months EBITDA margin is -7899%. |
| What is the current EV/EBITDA multiple of CG Oncology? | Current EBITDA multiple of CG Oncology is -9.0x. |
| What is the current FCF of CG Oncology? | CG Oncology's last 12 months FCF is -$111M. |
| What is CG Oncology's FCF margin? | CG Oncology's last 12 months FCF margin is -6259%. |
| What is the current EV/FCF multiple of CG Oncology? | Current FCF multiple of CG Oncology is -11.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
